Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cancer.

In summary, first-line SOX plus sintilimab for advanced gastric cancer shows a clear trend and advantage over conventional chemotherapy.

also in 19,460 other papers

In summary, ORRs in the SOX + sintilimab group were 91.4% by TRG and 70.4% by RECIST 1.1, numerically higher than in P-SOX (61.1 and 59.3%) and DOF (52.9 and 55.0%), although differences did not reach statistical significance (Table 1 ).

also in 111,027 other papers